Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. biopsense

BiopSense SIGNED

Proof of concept and pre-commercialisation of personalised liquid biopsies in cancer therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BiopSense project word cloud

Explore the words cloud of the BiopSense project. It provides you a very rough idea of what is the project "BiopSense" about.

steering    platform    polymorphism    prep    service    group    post    started    biotech    ipr    transferring    agena    university    customized    negotiations    closest    designing    sensitivity    biomarkers    international    lab    conferences    oncology    licensors    follow    extremely    extended    health    licensing    automated    flexible    kit    commercialization    consist    allowed    options    continue    diagnostics    accuracy    nucleotide    boosting    preparation    40    hospitals    price    centers    panels    blood    innovation    consultation    period    personalized    cheaper    complete    single    device    medical    competitor    market    liquid    business    either    medication    biopsies    point    determined    trl    spectrometric    upgrading    clarified    care    shield    cog    components    investors    presented    erc    chip    local    treatment    chemistry    personalised    invention    ultraseek    screening    panel    diagnostic    partnering    convention    mass    patent    sensitive    detection    cancer    investor    competing    operation    spin    combined    verified    companies   

Project "BiopSense" data sheet

The following table provides information about the project.

Coordinator		 JYVASKYLAN YLIOPISTO 

Organization address
address: SEMINAARINKATU 15
city: JYVASKYLA
postcode: 40100
website: http://www.jyu.fi

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Finland [FI]
 Total cost 149˙999 €
 EC max contribution 149˙999 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    JYVASKYLAN YLIOPISTO FI (JYVASKYLA) coordinator 149˙999.00

Map

 Project objective

Extremely high sensitivity is needed for the detection of cancer biomarkers during the follow-up of the treatment or post-operation period. We have identified a novel technology that enables very sensitive detection of single-nucleotide polymorphism from blood, enabling point-of-care screening of liquid biopsies. Our diagnostics platform will consist of new chemistry and device, and is an open system for designing new diagnostic targets. This will enable customized follow-up of the cancer medication in local hospitals and health care centers. The technology is based on our invention (US patent allowed) further developed in the ERC CoG project, but will have features for automated sample preparation and lab-on-chip design, which need to be verified and combined in the complete platform. For pre-commercialization of the technology, the sensitivity and accuracy of the chemistry will be determined and compared against competing mass spectrometric platform (UltraSEEK by Agena), upgrading our technology from phase TRL 4 to TRL 5. Patent shield of the technology is extended and options for transferring IPR from the University are clarified. Results are presented in investor convention and oncology conferences, and negotiations with investors and out-licensors are started. Three international biotech companies take part in the steering group. The technology allows business potential in device and kit production, but especially in international service business for personalised panel components and medical consultation. The expected price of the device and sample prep will be 30-40% cheaper than that of the closest competitor, but even better it allows flexible design of personalized diagnostic panels. The development for boosting the innovation to market will continue either through a spin-out supported by international investors, together with partnering companies, or through out-licensing.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOPSENSE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOPSENSE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

DIAPASoN (2019)

Differential Program Semantics

Read More